PHOENIX (January 20, 2015) – The Arizona Commerce Authority (ACA) today announced 10 finalists in the Fall 2014 Arizona Innovation Challenge (AIC), its bi-annual business plan competition that awards talented entrepreneurs who are solving today’s most challenging problems with technology-based solutions. Read More
NuvOx Pharma, a Tucson based biotechnology company, announced that a manuscript describing results of the Company’s product dodecafluoropentane emulsion (DDFPe) in reducing damage from myocardial infarction (MI) has been published in the journal Cardiovascular Drugs and Therapy Read More
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has received a $1Million grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma, (NCI Phase II SBIR, R44CA144817 - 02A1)". Read More
NuvOx, a Tucson, Arizona based developer of dodecafluoropentane (DDFP) based oxygen therapeutics, is adding three sites to its Phase I glioblastoma multiforme (GBM) trial of NVX108 in Australia, said Chief Business Officer David Wilson. Read More
Tucson, Arizona September 13, 2014-...Tucson-based biotech startup NuvOx Pharma has begun a Phase Ib clinical trial of its new drug — an oxygen-delivery agent — in patients with glioblastoma multiforme, a rare but particularly deadly form of brain cancer. Read More
Tucson, Arizona September 10, 2014-NuvOx Pharma has been awarded a Phase I Small Business Innovative Research contract (contract # HHSN268201400045C) for “Development of Molecular Imaging Agents and Methods to Detect High Risk Atherosclerotic Plaque” by the National Heart, Lung, and Blood Institute (NHLBI). Read More
Tucson, AZ, September 07, 2014- NuvOx Pharma has been issued a patent covering NuvOx core technology of dodecafluoropentane emulsion. US Patent No. 8,822,549, issued on September 4, 2014, entitled, “Buffered Oxygen Therapeutic,” has claims for buffered formulations of dodecafluoropentane emulsion (DDFPe). Read More
Tucson, AZ, August 07, 2014- NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer. Read More
To read more news about NuvOx Pharma, please visit our news page.
This is a comprehensive presentation of the company's Oxygen Nanotechnology Platform for treating life threatening conditions.
Dr. Unger has pioneered original research, championed the clinical translation of his research products, and founded companies in the technology-based private sector to market these products. Dr. Unger's products are routinely used in clinical diagnostic tests that impact the lives of Arizonans and improve healthcare world-wide.
NuvOx Pharma's CBO, David Wilson presents life saving innovation at AZBio Expo 2013
11th in a series of interviews from the ICUS Bubble Conference
An 88-year-old woman’s startling ophthalmologic symptoms were wrongly attributed to infection during [...]
Tumor markers continue to be used despite uncertainty surrounding their usefulness in cancer screeni [...]
Head and neck cancer patients with metastatic disease present unique challenges, typically associate [...]
The 5-year survival rate in esophageal cancer, although poor, has improved over the past decade. A n [...]
Prostate cancer – the most common malignancy in men – is often managed with radiotherapy. Treatment [...]